EISAI INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EISAI INC, and what generic alternatives to EISAI INC drugs are available?
EISAI INC has eleven approved drugs.
There are twelve US patents protecting EISAI INC drugs.
There are three hundred and ten patent family members on EISAI INC drugs in forty-two countries and thirty-nine supplementary protection certificates in eighteen countries.
Summary for EISAI INC
International Patents: | 310 |
US Patents: | 12 |
Tradenames: | 8 |
Ingredients: | 7 |
NDAs: | 11 |
Drug Master File Entries: | 1 |
Drugs and US Patents for EISAI INC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-001 | Oct 18, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | 11,090,386 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | 10,407,393 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | 9,006,256 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EISAI INC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-002 | Nov 14, 2008 | 8,076,362*PED | ⤷ Try a Trial |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 5,985,864 | ⤷ Try a Trial |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 4,895,841 | ⤷ Try a Trial |
Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | 8,097,648 | ⤷ Try a Trial |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 6,140,321 | ⤷ Try a Trial |
Eisai Inc | BANZEL | rufinamide | SUSPENSION;ORAL | 201367-001 | Mar 3, 2011 | 6,740,669*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for EISAI INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Orally Disintegrating Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-06-30 |
➤ Subscribe | Tablets | 23 mg | ➤ Subscribe | 2013-07-09 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Capsules | 4 mg and 10 mg | ➤ Subscribe | 2019-02-13 |
➤ Subscribe | Tablets | 100 mg, 200 mg and 400 mg | ➤ Subscribe | 2012-11-14 |
International Patents for EISAI INC Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Luxembourg | 91854 | ⤷ Try a Trial |
Israel | 195282 | ⤷ Try a Trial |
Japan | 2009215313 | ⤷ Try a Trial |
South Korea | 102329681 | ⤷ Try a Trial |
South Korea | 20170122734 | ⤷ Try a Trial |
South Korea | 20130097776 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EISAI INC Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1415987 | 553 | Finland | ⤷ Try a Trial | |
0994863 | 07C0037 | France | ⤷ Try a Trial | PRODUCT NAME: MODIFICATION CRISTALLINE A DU RUFINAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/378/001 DU 20070116; REGISTRATION NO/DATE AT EEC: EU/1/06/378/001-016 DU 20070116 |
1698623 | PA2015039 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528 |
1087960 | 394 | Finland | ⤷ Try a Trial | |
1415987 | 15C0070 | France | ⤷ Try a Trial | PRODUCT NAME: LENVATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1002 20150601 |
1698623 | PA2015039,C1698623 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: LENVATINIBAS; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.